Edgar Filing: Stolz Brian M. - Form 4

0 1 D .

FORM 4 UNITED STATES SECURITIES AND EXCHANCE COMMISSION								-	PPROVAL		
Check this box						NGE (OMB Number:	3235-0287		
box STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES							Expires:	January 31, 2005			
							burden hou	average irs per			
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,											
ses)											
			2. Issuer Name and Ticker or Trading Symbol				5. Relationship of Reporting Person(s) to Issuer				
							(Check all applicable)				
ïrst) (Mie	ddle)	3. Date of Earliest Transaction (Month/Day/Year)				Director10% Owner XOfficer (give titleOther (specify					
RMACEUTI AL,IN, 7150 ROAD	CALS	08/10/20	011				· · · · · · · · · · · · · · · · · · ·		СНСО		
Filed(Mont				-				6. Individual or Joint/Group Filing(Check			
								Applicable Line) _X_Form filed by One Reporting Person			
A6 L5N 8M5	5						Person	Note than one Re	porting		
tate) (Z	Zip)	Table	I - Non-De	erivative S	ecuri	ties Aco	quired, Disposed of	f, or Beneficial	lly Owned		
itle of urity (Month/Day/Year) 2A. Deemed (Month/Day/Year) Execution Date, if any (Month/Day/Year)		on Date, if	3.4. SecuritiesTransactionAcquired (A) orCodeDisposed of (D)(Instr. 8)(Instr. 3, 4 and 5)				SecuritiesHBeneficially(OwnedH	Form: Direct (D) or Indirect (I)			
24/2011			Code V A	Amount 5,230 (1) (2)	(D) A	Price \$ 0		D			
	STATEMI Filed pursu Section 17(a) ses) of Reporting Per irst) (Mi RMACEUTION ACEUTION ACEUTION COAD treet) A6 L5N 8M2 tate) (Z ansaction Date th/Day/Year)	STATEMENT OI Filed pursuant to S Section 17(a) of the I 30(h) ses) of Reporting Person * "irst) (Middle) RMACEUTICALS AL,IN, 7150 ROAD treet) A6 L5N 8M5 tate) (Zip) ansaction Date 2A. Deen th/Day/Year) Executio any (Month/I	Wash STATEMENT OF CHANG Filed pursuant to Section 16 Section 17(a) of the Public Uti 30(h) of the Inv Section 17(a) of the Public Uti 30(h) of the Inv Section 17(a) of the Public Uti 30(h) of the Inv Section 17(a) of the Public Uti 30(h) of the Inv Section 17(a) of the Public Uti 30(h) of the Inv Section 17(a) of the Public Uti 30(h) of the Inv Symbol Valeant Internation Alto Matceuric ALS Alto Matceuric ALS Alto Matceuric ALS Alto Matceuric ALS Alto LSN 8M5 tate) (Zip) Table ansaction Date 2A. Deemed thi/Day/Year) Execution Date, if any (Month/Day/Year)	Washington, I STATEMENT OF CHANGES IN B SECURI Filed pursuant to Section 16(a) of the Section 17(a) of the Public Utility Holdid 30(h) of the Investment Of 30(h) of the Investment Of 30(h) of the Investment Of Symbol Ses) of Reporting Person [*] 2. Issuer Name and Y Symbol Valeant Pharmace International, Inc. (Middle) 3. Date of Earliest Tra (Month/Day/Year) RMACEUTICALS 08/10/2011 At If Amendment, Date Filed(Month/Day/Year) Table I - Non-De ansaction Date 2A. Deemed Af Lif Amendment, Date Filed(Month/Day/Year) Ach LSN 8M5 tate) (Zip) Table I - Non-De ansaction Date 2A. Deemed ansaction Date 2A. Deemed 3. Ath/Day/Year) Keccution Date, if Transactio any Code Kode V	Washington, D.C. 205 STATEMENT OF CHANGES IN BENEFIC SECURITIES Filed pursuant to Section 16(a) of the Securiti Section 17(a) of the Public Utility Holding Com 30(h) of the Investment Company ses) of Reporting Person [*] of Reporting Person [*] (Middle) 3. Date of Earliest Transaction (Month/Day/Year) RMACEUTICALS AL,IN, 7150 ROAD Table I - Non-Derivative S A6 L5N 8M5 tate) 3. A the Security Transaction Date 2A. Deemed ansaction Date 2A. Deemed 3. A the Security Transaction Acquired any Code Disposed (Month/Day/Year) Code Disposed Code Last V Amount	Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL SECURITIES Filed pursuant to Section 16(a) of the Securities ExSection 17(a) of the Public Utility Holding Company 30(h) of the Investment Company Act 30(h) of 10(honth/Day/Year) Instructional International Internatinte International International International	Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OW SECURITIES Filed pursuant to Section 16(a) of the Securities Exchang Section 17(a) of the Public Utility Holding Company Act of 19- 30(h) of the Investment Company Act of 19- 30(h) Valeant Pharmaceuticals International, Inc. [VRX] irst) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) RMACEUTICALS 08/10/2011 AL,IN, 7150 08/10/2011 AG L5N 8M5 4. If Amendment, Date Original Filed(Month/Day/Year) A6 L5N 8M5 3. 4. Securities ansaction Date 2A. Deemed 3. 4. Securities Act ansaction Date 2A. Deemed 3. 4. Securities (Month/Day/Year) (Instr. 8) (Instr. 3, 4 and 5) (A) Code V Amount (D) Price (A) Code V Amount (D) Price	Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1935 or Section 30(h) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 ses) of Reporting Person [*] 2. Issuer Name and Ticker or Trading Symbol Valeant Pharmaceuticals International, Inc. [VRX] International, Inc. [VRX] Check MACEUTICALS O8/10/2011 A If Amendment, Date Original Filed(Month/Day/Year) A If Amendment, Date Original Filed(Month/Day/Year) A Securities S. Amount of Securities Acquired, Disposed of DN Beneficially OW Person A Securities S. Amount of Securities Acquired, Name Securities Se	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1935 or Section 30(h) of the Investment Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 ses) of Reporting Person ¹ 2. Issuer Name and Ticker or Trading Symbol Valeant Pharmaceuticals International, Inc. [VRX] irst) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) RMACEUTICALS ROAD treet) 4. If Amendment, Date Original Filed(Month/Day/Year) A6 L5N 8M5 tate) (Zip) Table I - Non-Derivative Securities A6 L5N 8M5 tate) (Zip) Table I - Non-Derivative Securities ansaction Date 2A. Deemed th/Day/Year) (Instr. 8) (Instr. 3, 4 and 5) (Month/Day/Year) (Instr. 8) (Instr. 3, 4 and 5) Code V Amount (D) Price (A) (A) (A) (A) (A) (A) (A) (A)		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: Stolz Brian M. - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. l De Sec (In
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Restricted Share Units	\$ 0	08/10/2011		А	45,000 (4)	(5)	(5)	Common Shares, no par value	45,000	

Reporting Owners

Reporting Owner Name / Address		Relationships					
		Director	10% Owner	Officer	Other		
Stolz Brian M. VALEANT PHARMACEUTICALS INTERNATIONAL,IN 7150 MISSISSAUGA ROAD MISSISSAUGA, A6 L5N 8M5				EVP, Administration and CHCO			
Signatures							
by: Nicholas Zanoni for Brian Stolz	10/26/2011						

**Signature of Reporting Person

Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Represents Restricted Share Units received under an employee Share Matching Program ("Matching RSUs") in connection with the
- (1) officer's purchase of Company common stock. Each Matching RSU represents a contingent right to receive one share of common stock, no par value, of Valeant Pharmaceuticals International, Inc
- 1/3 of the Matching RSUs will vest each on the first, second and third anniversary of the date of grant subject to contingent employment (2)and retention of the corresponding purchased shares.
- (3) This number represents 5,230 common shares purchased by the officer that were previously reported in Table 1.
- Each Restricted Share Unit ("RSUs") represents a contingent right to receive between zero and three common shares, no par value, of (4) Valeant Pharmaceuticals International, Inc. ("Valeant"), subject to performance based vesting criteria. See note (5).
- (5) The performance based RSUs will vest based on total shareholder return (TSR) between a price of \$51.7555 starting on August 10, 2011 and the average stock price for the prior 20 trading days as of three measurement dates: 25% would vest on May 10, 2014, 50% on August 10, 2014 and 25% on November 10, 2014. Unit vesting is contingent on TSR performance between 15% and 45% into between

Edgar Filing: Stolz Brian M. - Form 4

one and three shares of common stock, respectively, with early vesting possible at higher TSR levels.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.